Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1Recruiting 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Genitourinary 1

Conditions

Colorectal Neoplasms 50Neoplasms 13Neoplasm Metastasis 12Gastrointestinal Stromal Tumors 10Carcinoma, Hepatocellular 7Glioblastoma 5Colonic Neoplasms 5Sarcoma 4Stomach Neoplasms 3Parkinson Disease 4, Autosomal Dominant Lewy Body 3Ovarian Neoplasms 3Liver Neoplasms 3Rhabdomyosarcoma 2Rectal Neoplasms 2Pancreatic Neoplasms 2Gallbladder Neoplasms 2Esophageal Neoplasms 2Colorectal Cancer Metastatic 2Cholangiocarcinoma 2Carcinoma, Renal Cell 2Carcinoma, Non-Small-Cell Lung 2Bile Duct Neoplasms 2Advanced Cancer 2Wilms Tumor 1Urothelial Cancer (Urinary Bladder, Ureters, or Renal Pelvis Cancer) 1Thymoma 1Squamous Cell Carcinoma of Head and Neck 1Somatostatinoma 1Solid Tumor 1Sarcoma, Ewing 1

Interventions

pembrolizumab 25Gemcitabine 21Nivolumab 17Cisplatin 17atezolizumab 14Carboplatin 11avelumab 9vinflunine 7Ipilimumab 7Paclitaxel 6Docetaxel 5enfortumab vedotin 4cabazitaxel 4Pemetrexed 4Mitomycin 4cabozantinib 3Taxes 3Rogaratinib 3Magnetic Resonance Spectroscopy 3Injections 3Albumin-Bound Paclitaxel 3tremelimumab 2sacituzumab govitecan 2pemigatinib 2niraparib 2lenvatinib 2bempegaldesleukin 2apatorsen 2XRP6258 2Vitamin D 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Carcinoma, Transitional Cell × regorafenib × Clear all
NCT02795156 2023-12-05

Study Assessing Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations

SCRI Development Innovations, LLC

Phase 2 Completed
100 enrolled 14 charts
GenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡